Filing summary
Entity and period: The supplied filing is Salarius Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing identified as Decoy Therapeutics Inc. The summary below reflects Salarius’s filing.
Business context and reporting period
Salarius is a clinical-stage biopharmaceutical company developing cancer treatments. Its pipeline includes seclidemstat (SP-2577), in clinical development, and SP-3164, in IND-enabling studies. It has no products approved for sale and has generated no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 or comparison |
|---|---|---|
| Grant revenue | $0 | $1.27 million |
| Research and development expense | $4.44 million | $1.74 million |
| General and administrative expense | $1.68 million | $1.33 million |
| Net loss | $6.11 million | $1.85 million |
| Basic and diluted loss per share | $0.13 | $0.06 |
| Cash used in operating activities | $3.52 million | $2.72 million |
| Cash used in investing activities | $1.50 million | $0 |
At March 31, 2022, cash and cash equivalents were $24.19 million, working capital was $22.8 million, total assets were $35.51 million, and total liabilities were $2.09 million. The balance sheet reports no interest-bearing debt. Accumulated deficit was $38.31 million. No operating margin was reported; the company recorded an operating loss of $6.12 million.
Cash and cash equivalents declined $5.02 million during the quarter. Financing activities provided no cash in Q1 2022, compared with $28.22 million in Q1 2021, when equity sales and warrant exercises generated proceeds. Management states that recurring losses and the lack of product revenue raise substantial doubt about the company’s ability to continue as a going concern, and that existing cash may not fund operations for one year from issuance of the financial statements.
Material changes and unusual items
- R&D expense rose 155%, reflecting higher outsourced, personnel, and clinical-trial costs and the addition of SP-3164. Q1 R&D included $1.99 million of acquired in-process research and development expense.
- On January 12, 2022, Salarius acquired SP-3164-related assets from DeuteRx for $2.0 million: $1.5 million in cash and 1 million common shares valued at approximately $0.5 million. Potential future milestone and royalty payments also apply.
- Grant revenue fell to zero because Salarius had reached the maximum eligible CPRIT spending; it reported a $1.61 million CPRIT receivable at quarter-end and expected to collect it.
- After quarter-end, a common-stock and warrant offering closed April 26, 2022, generating $2.3 million gross proceeds before fees and expenses. The company sold 9,339,436 shares and warrants for up to 7,004,578 additional shares.
Outlook, risks, and contingencies
Management expects significant expenses and operating losses for at least the next several years and says additional capital will be needed. It may seek equity or debt financing, collaborations, or technology partnerships, but gives no assurance of obtaining financing on acceptable terms. Failure to raise capital could delay, scale back, or discontinue development. The CPRIT grant agreement expires November 30, 2022; the company reported that allowable grant funds had been expended and that $1.6 million remained receivable. COVID-19 could disrupt clinical operations, although Salarius reported minimal disruption to date.
Salarius also disclosed a Nasdaq minimum-bid-price deficiency. As of May 11, 2022, the reported closing share price was $0.19; the company was evaluating options, including a potential reverse stock split, and warned that failure to regain compliance could result in delisting. The filing reported no material legal proceedings and no significant change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Check subsequent cash collections of the CPRIT receivable, grant-agreement status, and the timing and adequacy of further financing given the going-concern disclosure.
- Review the April 2022 offering’s net proceeds, warrant terms, and resulting dilution and share count.
- Track clinical and regulatory progress for SP-2577 and SP-3164, including spending and development timelines.
- Verify Nasdaq listing-compliance developments and any action on the proposed reverse stock split.